Abstract: This composition contains, by way of main active principle, in a pharmaceutically acceptable carrier, at least one substance belonging to the carotenoid family and chosen, in particular, from the group consisting of .alpha.-carotene, .delta.-carotene, .gamma.-carotene, .beta., .beta.-carotene-4,4'-dione, ethyl 8'-apo-.beta.-caroten-8'-oate, .beta.-apo-8'-carotenal, .psi.,.psi.-carotene, .psi.,.psi.-carotene-16,16'-diol and .psi.,.psi.-caroten-16-ol. This composition preferably contains from 0.001 to 10% by weight of active principle relative to the total weight of the composition and takes the form of a suspension, tablets or gelatin capsules. The pharmacological activity of this drug is an activity which inhibits comedo formation, the latter being due to an irritation caused by an excess of lipid oxide (oxidized squalene).
Abstract: A gallstone dissolver comprises the following active ingredients (A) and (B);(A) a compound selected from the group consisting of fatty acid monoglycerides of C-6 to C-12, fatty acid diglycerides in liquid phase at 30.degree. C., fatty acid triglycerides in liquid phase at 30.degree. C., and fatty acids in liquid phase at 30.degree. C., and(B) a monoterpene.The coexistence of the fatty acid and monoterpene in the gallstone dissolver accelerates the sulubility and dissolving velocity of cholesterol gallstones.A nonionic surfactant such as a polyoxyethylene sorbitan fatty acid ester, glycerin fatty acid ester, etc. may also be added to the above dissolver to further improve the performance of the dissolver.
Abstract: A series of alkanoarachidonic acids have been prepared as modulators of the arachidonic acid cascade to increase the production of biologically desirable compounds and minimize the production of biologically undesirable compounds. Examples of desirable compounds in this respect comprise postaglandins and thromboxanes whereas undesirable compounds comprise the mono- and polyhydroxyarachidonic acids and leukotrienes. The alkanoarachidonic acids and their intermediates are of the general formula: ##STR1## and at least one of X, Y, and Z is lower alkano and is hydrogen when not lower alkano; the esters and salts of the acids are also prepared. The acids, esters and salts may be used as anti-anaphylaxis or anti-thrombosis agents.
Type:
Grant
Filed:
September 27, 1984
Date of Patent:
July 26, 1988
Assignee:
Research Corporation
Inventors:
Kyriacos C. Nicolaou, Nicos A. Petasis, Wen-Sen Li, Tamara Ladduwahetty, Jared L. Randall, Stephen E. Webber, Pedro E. Hernandez
Abstract: Compounds useful in treating cardiovascular disorders such as thrombosis, hypertension and atherosclerosis are depicted in formulas (1), (2) and (3): ##STR1## wherein: A is --C.tbd.C--, trans --HC.dbd.CH--, --CH.sub.2 CH.sub.2 -- or --CH.dbd.CHCH.sub.2 --;X is lower alkoxy, hydroxy, or (2,2,2)-trifluoroethoxy;Y is hydrogen, exo-(lower alkyl) or endo-(lower alkyl);is an integer of 2-4;R.sub.1 is --CH.sub.2 OH, --CHO, --CO.sub.2 R or --CO.sub.2 H, and the olefin formed by the R.sub.1 (CH.sub.2).sub.n CH.dbd. moiety is either (E) or (Z);R.sub.2 is hydrogen or methyl, or optionally --CH.dbd.CH.sub.2 when A is --CH.dbd.CHCH.sub.2 --; andR.sub.3 is linear or branched alkyl, alkenyl or alkynyl having 5-10 carbon atoms, ##STR2## --(CH.sub.2).sub.m -phenyl or CH.sub.
Abstract: Compounds useful in treating cardiovascular disorders such as thrombosis, hypertension, and atherosclerosis are compounds depicted in formulas (1), (2), and (3): ##STR1## wherein: Y is exo-(lower alkyl) or endo-(lower alkyl);n is 2 or 3;R.sub.1 is CH.sub.2 OH, CHO, CO.sub.2 R or CO.sub.2 H;R.sub.2 is hydrogen or methyl; andR.sub.3 is linear or branched alkyl having 5-10 carbon atoms, ##STR2## or --(CH.sub.2).sub.m -phenyl optionally substituted with lower alkyl, lower alkoxy, trifluoromethyl, or halogen,in whicha is 0, 1 or 2;b is 3-7;m is 1 or 2; andR is ##STR3## wherein X is ##STR4## in which each R.sub.4 is independently hydrogen or lower alkyl having 1-6 carbon atoms, and the pharmaceutically acceptable, non-toxic salts and esters thereof.
Abstract: A sex pheromone composition for southwestern corn borer male moths consisting essentially of Z9-Hexadecenal in an amount of about 16-26% by weight, Z11-Hexadecenal in an amount of about 56-85% by weight, and Z13-Octadecenal in an amount of about 6-10% by weight.
Type:
Grant
Filed:
October 8, 1985
Date of Patent:
December 30, 1986
Assignee:
The United States of America as represented by the Secretary of Agriculture
Inventors:
Paul A. Hedin, Frank M. Davis, Joseph C. Dickens, Marcus L. Burks, Thomas G. Bird
Abstract: Compounds useful in treating cardiovascular disorders such as thrombosis, hypertension, and atherosclerosis are compounds depicted in formulas (1), (2), and (3): ##STR1## wherein: n is 2 or 3;R.sub.1 is CH.sub.2 OH, CHO, CO.sub.2 R or CO.sub.2 H;R.sub.2 is hydrogen or methyl; andR.sub.3 is linear or branched alkyl having 5-10 carbon atoms, ##STR2## optionally substituted with lower alkyl, lower alkoxy, trifluoromethyl, or halogen,in whicha is 0, 1 or 2;b is 3-7;m is 1 or 2; andR is ##STR3## in which each R.sub.4 is independently hydrogen or lower alkyl having 1-6 carbon atoms,and the pharmaceutically acceptable, non-toxic salts and esters thereof.
Type:
Grant
Filed:
March 27, 1985
Date of Patent:
August 26, 1986
Assignee:
Syntex (U.S.A.) Inc.
Inventors:
Arthur F. Kluge, Anthony L. Willis, Counde O'Yang
Abstract: A method of inactivating enveloped virus comprises contacting said virus with a virucidally effective amount of a C.sub.20-24 linear polyunsaturated acid, aldehyde or primary alcohol having 5-7 double bonds, a pharmaceutically acceptable salt of said acid, or a mixture thereof. Topical administration of the virucide is preferred and is effective in treating lesions associated with herpes infections. Pharmaceutical compositions for use in the present method are provided.
Type:
Grant
Filed:
July 30, 1982
Date of Patent:
April 23, 1985
Assignee:
The Vinoxen Company, Inc.
Inventors:
Emanuel Revici, Bob E. Sherwood, Herman P. Benecke, John M. Rice, Richard W. Geisler
Abstract: This application relates to the administering of fatty aldehydes (and acids) to patients suffering from Multiple Sclerosis, for therapeutic purposes.